Search Results for: "genentech v pfizer bevacizumab"

Bevacizumab Litigation Update: Pfizer Answers Genentech’s Complaint and Genentech Moves to Dismiss Counterclaims

On April 29, 2019, Pfizer answered Genentech’s complaint alleging infringement of 22 patents based on Pfizer’s submission of an aBLA seeking U.S. FDA approval of a biosimilar of Avastin® (bevacizumab).  In its answer, Pfizer denied Genentech’s allegations of patent infringement and violations of the BPCIA’s patent dance procedures.  Pfizer also…

Read More

BPCIA Litigations

Pending U.S. District Court BPCIA Litigations Litigation Accused Biosimilar [status] Reference Product Complaint Filed Status/Outcome District Court Appeal Amgen v. Hospira, No. 20-201 (D. Del.) NYVEPRIA (pegfilgrastim-apgf) [approved] NEULASTA [litigation #5] Feb. 11, 2020 Pending Genentech v. Samsung Bioepis, No. 20-859 (D. Del.) SB8 (bevacizumab biosimilar) [not approved] AVASTIN [litigation…

Read More